Cannabis Science CEO Sees Over 3,000 Shareholders Registering for Their Loyalty Gifts, as the Company Looks at Plans Coming Together to Unveil the Schematics of Its 360,000 sq. ft. Nevada Drug Development Complex Within the Next Few Days
COLORADO SPRINGS, CO--(Marketwired - May 3, 2016) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicine, is currently processing more than 3,000 shareholder requests for their "loyalty gift" from CEO Raymond C. Dabney. This is a remarkable number to say the least, as the company draws near the release of the schematics for its 360,000 sq. ft., Nevada drug development complex later this week.
"I am simply amazed. I never imagined seeing the sheer number of shareholders expressing well wishes and success to our drug development programs. From shareholder interest in investing in the Nevada project, to just wanting to say Thank you with or without the gift is a true testament to the loyalty of the Cannabis Science investors. The number of emails I have received personally thanking me is astounding. It sure does feel good to have a small army backing you up when it's certainly been a battle in a war that rages on. At this point, I think we are becoming a major force in the conflict against critical ailments," stated Cannabis Science President & CEO, Co- Founder, Raymond C. Dabney.
"We are working our way through the documentation with my legal team, as quickly as possible to ensure our successful completion. With these overwhelming numbers coming in, we are thinking of a much simpler way to accommodate the gifts; we have some good ideas getting vetted right now. I want to see this closed out and completed by the end of this month. We have so many projects in front of us. Time to quit looking in the rear view mirror. It is time to look forward towards new developments and projects. We believe we are creating sustainable value for our shareholders," said Dabney.
"So much has changed so quickly. What is even more compelling: the company has verbally agreed to investors, associates, and/or partnerships for a number of its available parcels in the Nevada development. This level of excitement being expressed before we release the schematics tells me we are on to something big! We want to move forward at light speed. I feel this will take us to the next level. We will release the first version schematics for the Nevada facilities in a couple days. There will be some VERY pleasantly surprised people out there. I think the people have spoken, with the University, medical complex, and cultivation centers in one area is a serious community builder, so many new jobs, education, medical treatments, and many more economic growth advantages is the type of forward thinking required in this burgeoning Cannabis Industry to expand properly across the Country and around the world.
"I have even saved a few 1-acre parcels for our shareholders who have expressed serious interest and are waiting to hear back from me to review the schematics and the deal. Everyone will be able to review these documents at that point. 41 acres goes a long way and over 1,000 acres goes a lot further; we are going the distance regardless, just watch these next few moves," concluded Mr. Dabney
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.